ROCHESTER — Researchers at Mayo Clinic announced Wednesday that they have identified three specific gene types that account for a known two-to-three-fold increase in myeloma diagnoses among African-Americans.

Researchers also demonstrated the ability to study race and racial admixture more accurately using DNA analysis. The findings were published Wednesday in Blood Cancer Journal, a peer-reviewed journal that publishes articles related to hematologic malignancies and related disorders.

“Myeloma is a serious blood cancer that occurs two to three times more often in African-Americans than Caucasians,” said Dr. Vincent Rajkumar, a hematologist at Mayo Clinic and senior author of the study. “We sought to identify the mechanisms of this health disparity to help us better understand why myeloma occurs in the first place and provide insight into the best forms of therapy.”

Rajkumar and his colleagues studied 881 patients of various racial groups. Researchers found the higher risk of myeloma known to occur in African-Americans was driven by three specific subtypes of the cancer characterized by the presence of genetic translocations in cancer cells. Translocations are genetic abnormalities in cancer cells caused by the rearrangement of parts between nonhomologous chromosomes.

“Previous efforts to understand this disparity have relied on self-reported race rather than on genetic ancestry, which may have resulted in bias,” Rajkumar said. “A major new aspect of this study is that we identified the ancestry of each patient through DNA sequencing, which allowed us to determine ancestry more accurately.”

Rajkumar said there are efforts to enroll more minorities in clinical studies.

“However, it is equally, if not more important, to determine the mechanisms of racial disparities in terms of why cancers occur more often in certain racial groups. Our findings provide important information that will help us determine the mechanism by which myeloma is more common in African-Americans, as well as help us in our quest to find out what causes myeloma in the first place,” he said.

Rajkumar says study results also are important because response to cancer treatments vary based on the genetic subtype of cancer, and these findings will help researchers develop more effective treatment strategies for African-Americans with myeloma.